MX2021008984A - Inhibidor jak y metodo de preparacion del mismo. - Google Patents
Inhibidor jak y metodo de preparacion del mismo.Info
- Publication number
- MX2021008984A MX2021008984A MX2021008984A MX2021008984A MX2021008984A MX 2021008984 A MX2021008984 A MX 2021008984A MX 2021008984 A MX2021008984 A MX 2021008984A MX 2021008984 A MX2021008984 A MX 2021008984A MX 2021008984 A MX2021008984 A MX 2021008984A
- Authority
- MX
- Mexico
- Prior art keywords
- jak inhibitor
- preparation
- method therefor
- compound
- stereoisomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona un compuesto representado por una formula general I y una sal farmacéuticamente aceptable, estereoisómero, ester, profármaco, solvato o compuesto deuterado del mismo. El compuesto es un inhibidor de Quinasa de Janus (JAK) y puede prevenir y/o tratar una enfermedad inflamatoria o cáncer en humanos y/o animales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910088713 | 2019-01-30 | ||
| PCT/CN2019/127494 WO2020155931A1 (zh) | 2019-01-30 | 2019-12-23 | 一种jak抑制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008984A true MX2021008984A (es) | 2021-09-08 |
Family
ID=71839941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008984A MX2021008984A (es) | 2019-01-30 | 2019-12-23 | Inhibidor jak y metodo de preparacion del mismo. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220106319A1 (es) |
| EP (1) | EP3915989B1 (es) |
| JP (1) | JP7278649B6 (es) |
| KR (1) | KR20210120074A (es) |
| CN (1) | CN111499641B (es) |
| AU (1) | AU2019426113B2 (es) |
| BR (1) | BR112021014525A8 (es) |
| CA (1) | CA3127892A1 (es) |
| CO (1) | CO2021010415A2 (es) |
| DK (1) | DK3915989T3 (es) |
| ES (1) | ES2958160T3 (es) |
| FI (1) | FI3915989T3 (es) |
| MX (1) | MX2021008984A (es) |
| PH (1) | PH12021551844A1 (es) |
| PL (1) | PL3915989T3 (es) |
| PT (1) | PT3915989T (es) |
| WO (1) | WO2020155931A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118255769A (zh) * | 2022-12-28 | 2024-06-28 | 格格巫（珠海）生物科技有限公司 | 一种立体异构体的制备方法及中间体 |
| CN118420617A (zh) * | 2023-01-31 | 2024-08-02 | 格格巫（珠海）生物科技有限公司 | 一种化合物的晶型及其制备方法和用途 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0508036A (pt) * | 2004-02-27 | 2007-07-17 | Hoffmann La Roche | derivados fundidos de pirazola |
| DK2288610T3 (en) * | 2008-03-11 | 2016-11-28 | Incyte Holdings Corp | Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS |
| KR101335843B1 (ko) * | 2008-08-20 | 2013-12-02 | 조에티스 엘엘씨 | 피롤로[2,3-ｄ]피리미딘 화합물 |
| JP5629324B2 (ja) * | 2009-10-15 | 2014-11-19 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジン化合物 |
| JP5739446B2 (ja) | 2009-12-18 | 2015-06-24 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジン化合物 |
| WO2011078143A1 (ja) * | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
| IN2015DN00370A (es) | 2012-07-20 | 2015-06-12 | Zoetis Llc | |
| AU2014220357B2 (en) * | 2013-02-22 | 2017-04-27 | Pfizer Inc. | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of Janus- related Kinases (JAK) |
| WO2014146246A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors |
| WO2014146249A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors |
| CN105189508B (zh) * | 2013-03-19 | 2018-11-23 | 默沙东公司 | 作为janus激酶抑制剂的环烷基腈吡唑并吡啶酮 |
| US10174056B2 (en) * | 2015-05-29 | 2019-01-08 | Wuxi Fortune Pharmaceutical Co., Ltd | Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| CN108699072B (zh) * | 2016-02-16 | 2021-02-26 | 硕腾服务有限责任公司 | 用于制备7h-吡咯并[2,3-d]嘧啶化合物的方法 |
| US11524961B2 (en) * | 2017-01-23 | 2022-12-13 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | JAK kinase inhibitor and preparation method and use thereof |
| EP3601253B1 (en) * | 2017-03-28 | 2021-09-15 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
-
2019
- 2019-12-23 ES ES19913097T patent/ES2958160T3/es active Active
- 2019-12-23 MX MX2021008984A patent/MX2021008984A/es unknown
- 2019-12-23 AU AU2019426113A patent/AU2019426113B2/en active Active
- 2019-12-23 PH PH1/2021/551844A patent/PH12021551844A1/en unknown
- 2019-12-23 PL PL19913097.2T patent/PL3915989T3/pl unknown
- 2019-12-23 KR KR1020217027469A patent/KR20210120074A/ko active Pending
- 2019-12-23 JP JP2021543513A patent/JP7278649B6/ja active Active
- 2019-12-23 BR BR112021014525A patent/BR112021014525A8/pt unknown
- 2019-12-23 CN CN201911336860.1A patent/CN111499641B/zh active Active
- 2019-12-23 EP EP19913097.2A patent/EP3915989B1/en active Active
- 2019-12-23 CA CA3127892A patent/CA3127892A1/en active Pending
- 2019-12-23 PT PT199130972T patent/PT3915989T/pt unknown
- 2019-12-23 DK DK19913097.2T patent/DK3915989T3/da active
- 2019-12-23 FI FIEP19913097.2T patent/FI3915989T3/fi active
- 2019-12-23 US US17/426,933 patent/US20220106319A1/en active Pending
- 2019-12-23 WO PCT/CN2019/127494 patent/WO2020155931A1/zh active Application Filing
-
2021
- 2021-08-09 CO CONC2021/0010415A patent/CO2021010415A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7278649B2 (ja) | 2023-05-22 |
| CO2021010415A2 (es) | 2021-08-19 |
| FI3915989T3 (fi) | 2023-09-20 |
| BR112021014525A2 (pt) | 2021-09-28 |
| AU2019426113A1 (en) | 2021-09-09 |
| PH12021551844A1 (en) | 2022-05-23 |
| BR112021014525A8 (pt) | 2022-11-22 |
| JP2022518821A (ja) | 2022-03-16 |
| PT3915989T (pt) | 2023-10-02 |
| CN111499641B (zh) | 2021-06-04 |
| EP3915989B1 (en) | 2023-06-28 |
| PL3915989T3 (pl) | 2023-12-11 |
| JP7278649B6 (ja) | 2024-02-15 |
| DK3915989T3 (da) | 2023-09-18 |
| CA3127892A1 (en) | 2020-08-06 |
| ES2958160T3 (es) | 2024-02-02 |
| NZ779252A (en) | 2024-04-26 |
| KR20210120074A (ko) | 2021-10-06 |
| CN111499641A (zh) | 2020-08-07 |
| WO2020155931A1 (zh) | 2020-08-06 |
| US20220106319A1 (en) | 2022-04-07 |
| EP3915989A4 (en) | 2022-03-09 |
| EP3915989A1 (en) | 2021-12-01 |
| AU2019426113B2 (en) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021008984A (es) | Inhibidor jak y metodo de preparacion del mismo. | |
| MX2021012756A (es) | Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este. | |
| MX2022001421A (es) | Compuesto tetracíclico, método de preparación y uso del mismo. | |
| CL2022001731A1 (es) | Inhibidores de egfr. | |
| DOP2022000117A (es) | Inhibidores de kras g12c | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| ZA202311035B (en) | Phosphonyl derivative, and composition and pharmaceutical application thereof | |
| AU2018271990A1 (en) | Covalent inhibitors of KRAS | |
| PH12022551104A1 (en) | Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof | |
| TR201903322T4 (tr) | Kinaz inhibisyonu için heteroaril bileşikleri. | |
| CL2024000067A1 (es) | Compuestos antivirales | |
| PH12021550958A1 (en) | Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor | |
| NZ756231A (en) | A novel isoindoline derivative, a pharmaceutical composition and use thereof | |
| JOP20200059A1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| SG11201900868XA (en) | Ido1 inhibitor and preparation method and application thereof | |
| MY199779A (en) | Pyrrolopyrimidine compound and use thereof | |
| ZA202307945B (en) | Pyridopyrimidinone derivative, preparation method therefor, and use thereof | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| EA202191051A1 (ru) | Ингибитор аврора-киназы a для применения для лечения нейробластомы | |
| MX2021003662A (es) | Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo. | |
| MX2022006653A (es) | Compuestos para modular la actividad de fxr y usos de los mismos. | |
| MX394860B (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| CO2022008209A2 (es) | Compuesto que funciona como inhibidor de la quinasa del receptor de pdgf y composición | |
| PH12019550154B1 (en) | Azetidine derivative |